In medicine, we are trained to react to alarms. A monitor beeps. A CT scan lights up. A lab value crosses a dangerous threshold. We move.
Public health is harder. Sometimes the most important signal is not a siren, but a persistent hum. That is where mpox appears to be now.
The latest World Health Organization situation report should not send clinicians into panic, but it should pull mpox back into our peripheral vision. In May 2026, 32 countries reported 1,142 confirmed mpox cases and three deaths. The outbreak remains a WHO graded emergency, and all clades of monkeypox virus continue to circulate. Two-thirds of reported cases were in the WHO African Region, but the geography and epidemiology are no longer as tidy as many of us might wish.
The danger in 2026 is not that mpox looks exactly like it did in 2022. The danger is that it does not.
Real physician voices, twice a week
Free, and one click to unsubscribe.
In 2022, many clinicians in the U.S. and Europe learned to recognize mpox through a specific lens: painful genital or perianal lesions, sexual network transmission, and disproportionate impact among gay, bisexual, and other men who have sex with men. That pattern mattered. It still matters. But it is no longer sufficient.
Clade Ib, which has driven concern in parts of Africa, is no longer only an Africa-linked travel story. WHO has reported clade Ib detections and local transmission signals outside Africa, including in Europe and Asia. That does not mean mpox is suddenly a risk to everyone in the same way. It does mean our mental model has to evolve.
The CDC’s message for the United States is appropriately measured: The risk to most people remains low. As of June 2026, more than 20 clade I mpox cases had been reported in the U.S., all linked to travel from affected areas or exposure to someone with such travel. That is reassuring. But reassuring is not the same as irrelevant.
For clinicians, the practical question is not, “Should everyone be worried about mpox?” The better question is, “Will I recognize the patient in front of me who should be tested, counseled, vaccinated, or connected to public health?”
That distinction matters because low population risk can coexist with high individual stakes. Mpox can be severe, especially for immunocompromised patients, pregnant people, children, and those with barriers to care. It can also be missed when a clinician assumes the diagnosis belongs to another country, another clinic, or another patient population.
The Lancet Infectious Diseases recently framed the next phase of mpox around virus expansion, evolution, and immune recognition. That is a useful shift. The work ahead is no longer just emergency response. It is sustained control.
Sustained control is less dramatic than crisis response. It means keeping diagnostic pathways open after headlines fade. It means maintaining vaccine access for people at increased risk. It means asking travel and exposure questions without stigma. It means remembering that sexual health is public health, not a moral category. It means sequencing enough virus to know what is spreading, where, and in whom. It means not forcing every outbreak into the template of the last one.
This is also a communication challenge. If we overstate the risk, we lose trust. If we understate it, we lose time.
The right message is not “mpox is back” as if it ever truly left. Nor is it “nothing to see here.” The right message is: Mpox is still circulating, the virus is changing its footprint, and clinicians have a narrow but important role in keeping small problems from becoming large ones.
That role can be simple. Consider mpox in patients with compatible rashes, mucosal lesions, lymphadenopathy, proctitis, or unexplained painful skin lesions, especially when there is relevant travel, exposure, sexual network risk, or contact with a confirmed or suspected case. Know how to test in your local system before you need to. Offer vaccination to eligible patients without making them ask twice. Counsel patients with clarity: Mpox spreads mainly through close contact; risk is not evenly distributed; vaccination reduces risk and may reduce severity; and seeking care early helps protect both the patient and their community.
We should also be humble. Declining surveillance in some settings means confirmed case counts are not the same as true case counts. A thousand confirmed cases a month globally is not a catastrophe, but it is not disappearance. It is a reminder that pathogens exploit the space between attention cycles.
Clinicians do not need to become mpox experts overnight. But we do need to keep mpox in the differential, especially because the next patient may not match the picture we learned in 2022.
Public health rarely rewards vigilance in real time. When prevention works, nothing dramatic happens. No crowded ward. No frantic press conference. No emergency memo marked urgent. Just fewer missed cases. That should be enough.
Melvin Sanicas is an infectious disease physician.
